Pancreatic Cancer Research

ResearcherOncotab, IncActive in the last 2 years

Pinku Mukherjee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6782-3576; OpenAlex author ID A5045937236; NIH RePORTER profile ID 8556601. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 19)
Trials
0
Grants
8
Labs led
1
Collaborators
47
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 5 papers, 1 grant · 2014: 2 papers, 1 grant · 2015: 1 paper · 2016: 2 papers, 1 grant · 2017: none · 2018: 3 papers, 1 grant · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper, 2 grants · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper, 1 grant · 2026: 1 paper, 1 grant

Papers 27

  1. Untargeted Metabolomics Analysis Reveals Potential Metabolic Targets in Gemcitabine-Treated Pancreatic Cancer Cells. Last author DOI 10.3390/metabo16070471↗
  2. Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy. Last author DOI 10.3389/fimmu.2025.1618415↗
  3. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Last author DOI 10.1016/j.trsl.2022.08.010↗
  4. Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic O… Co-author DOI 10.1002/smll.202104449↗
  5. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2022.05.019↗
  6. Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fcell.2022.821875↗
  7. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models Last author DOI 10.3390/ijms22115587↗
  8. Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma Last author DOI 10.1101/2020.04.29.068577↗
  9. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal A… Last author DOI 10.3389/fonc.2019.00330↗
  10. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cells8091070↗
  11. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. Last author DOI 10.1186/s12885-018-4393-7↗
  12. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004. Last author DOI 10.1371/journal.pone.0193260↗
  13. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line. Last author DOI 10.18632/oncotarget.23966↗
  14. Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer. Co-author DOI 10.1002/ijc.30098↗
  15. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Last author DOI 10.1038/onc.2015.516↗
  16. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000371↗
  17. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Co-author DOI 10.1007/s00262-014-1527-x↗
  18. Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. Last author DOI 10.3389/fimmu.2014.00067↗
  19. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. Last author DOI 10.1002/jso.23316↗
  20. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Co-author DOI 10.1016/j.virol.2012.11.014↗
  21. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Last author DOI 10.1038/oncsis.2013.16↗
  22. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. Co-author DOI 10.1128/jvi.01412-13↗
  23. Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1128/jvi.02979-12↗
  24. MUC1 regulates PDGFA expression during pancreatic cancer progression. Last author DOI 10.1038/onc.2011.651↗
  25. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. Co-author DOI 10.1128/jvi.05640-11↗
  26. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Last author DOI 10.1038/onc.2010.526↗
  27. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Last author DOI 10.1158/0008-5472.can-10-4439↗

Grants 8

  1. Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment R44CA306447↗
  2. Optimized targeted radiotherapy of pancreatic cancer R41CA284997↗
  3. The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma R41CA265619↗
  4. An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer. R41CA265655↗
  5. Administrative Core P50CA102701↗
  6. Novel immunotherapy strategy for treatment of pancreatic cancer R41CA195947↗
  7. MUC1 regulation of TGF-beta function in pancreatic cancer cells R03CA166910↗
  8. MUC1 enhances Neuropilin-1 signaling in pancreatic ductal adenocarcinoma R15CA173668↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ru zhou · 4 shared grants, 2021–2026 · strength 3.19
  2. Ru Zhou · 8 shared papers, 2016–2025 · strength 1.03
  3. Rahul Puri · 1 shared grant, 2026 · strength 1.00
  4. Priyanka Grover · 8 shared papers, 2013–2022 · strength 0.70
  5. Sritama Nath · 9 shared papers, 2011–2022 · strength 0.68
  6. Mukulika Bose · 5 shared papers, 2019–2023 · strength 0.66
  7. Mahboubeh Yazdanifar · 5 shared papers, 2016–2022 · strength 0.46
  8. Didier Dréau · 4 shared papers, 2014–2022 · strength 0.43
  9. Mubin Tarannum · 2 shared papers, 2022 · strength 0.39
  10. Juan Luis Vivero-Escoto · 2 shared papers, 2022 · strength 0.39
  11. Arjun Prasad Tiwari · 1 shared paper, 2026 · strength 0.39
  12. John F. Maher · 2 shared papers, 2019–2025 · strength 0.37
  13. Shu-ta Wu · 4 shared papers, 2018–2020 · strength 0.37
  14. Lopamudra Das Roy · 8 shared papers, 2011–2016 · strength 0.31
  15. Dahlia M. Besmer · 8 shared papers, 2011–2014 · strength 0.26
  16. Mahnaz Sahraei · 5 shared papers, 2011–2021 · strength 0.26
  17. Shan Yan · 1 shared paper, 2022 · strength 0.19
  18. Md Akram Hossain · 1 shared paper, 2022 · strength 0.19
  19. Andrea M. Murphy · 5 shared papers, 2012–2013 · strength 0.19
  20. Valery Z. Grdzelishvili · 5 shared papers, 2012–2013 · strength 0.19
  21. Megan J Moerdyk-Schauwecker · 4 shared papers, 2012–2013 · strength 0.15
  22. Peter A Cohen · 1 shared grant, 2018 · strength 0.15
  23. Eduardo N Chini · 1 shared grant, 2018 · strength 0.15
  24. Wilma Lingle · 1 shared grant, 2018 · strength 0.15
  25. Thomas C. Smyrk · 1 shared grant, 2018 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.